Proteomic Profile of Sorafenib Resistance in Hepatocellular Carcinoma; GRP78 Expression Is Associated With Inferior Response to Sorafenib

Conclusion: GRP78 can be a predictive biomarker in HCC patients treated with sorafenib. Strategies designed to inhibit the GRP78-related pathway may overcome sorafenib resistance.

Source: Cancer Genomics and Proteomics - October 27, 2019 Category: Cancer & Oncology Authors: FENG, Y.-H., TUNG, C.-L., SU, Y.-C., TSAO, C.-J., WU, T.-F. Tags: Article Source Type: research